JP5662766B2 - 癌関連タンパク質を標的とするRNAiプローブ - Google Patents
癌関連タンパク質を標的とするRNAiプローブ Download PDFInfo
- Publication number
- JP5662766B2 JP5662766B2 JP2010250838A JP2010250838A JP5662766B2 JP 5662766 B2 JP5662766 B2 JP 5662766B2 JP 2010250838 A JP2010250838 A JP 2010250838A JP 2010250838 A JP2010250838 A JP 2010250838A JP 5662766 B2 JP5662766 B2 JP 5662766B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- clu
- clusterin
- sirna
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
カルシュ(Carthew)ら、Current Opinions in Cell Biology 13、244〜248頁(2001)
エルバシル(Elbashir)ら、Nature 411、494〜498頁(2001)
1)細胞の調製
抗生物質(ペニシリン/ストレプトマイシン)を含まない5%のFBSを含む適当な培地中のLNCaP細胞0.5×106個を(PC3細胞では、ウェル当たり0.3×106個の密度で)6穴プレートの各ウェルに播く。
40〜50%コンフルエントになるまで、細胞を37ECの加湿下5%CO2インキュベータ内でインキュベートする。
2)siRNAの調製
以下のsiRNA希釈液を微量遠心チューブに調製する。各ウェル当たり、0.01〜100nM。
3)以下のトランスフェクション試薬希釈液を微量遠心チューブに調製する。
6穴プレートの各ウェルについて、OligoFECTAMINE(商標)試薬4mlをOPTI−MEM(商標)11mlで希釈し、室温で10分間インキュベートする。
4)希釈したOligoFECTAMINE(商標)を、希釈したsiRNA二本鎖希釈液と合わせて、反転により穏やかに混合する。
5)室温で20分インキュベートする。
6)ウェルから培地を取り除き、Opti−MEM(商標)800mlと交換する。
7)細胞にトランスフェクション複合体200mlを上層する。
8)37℃のCO2インキュベータ内で4時間インキュベートする。
9)15%FBSを含む培地500mlを添加する。
10)24時間後にリアルタイムPCRにより遺伝子発現をチェックするか、又は
11)1、6、12、24、48、72及び96時間後にウエスタンブロットによりタンパク質発現をチェックする。
Claims (5)
- 各々の鎖が23以下の塩基長を有し、標的遺伝子の転写産物であるmRNAの分解を仲介するか翻訳を阻害するのに有効な配列を有する二重鎖のRNA分子であって、前記標的遺伝子がクラステリンをコードする遺伝子であり、該二重鎖RNA分子の各々の鎖がRNA部分とDNA部分を含み、該RNA部分はそれぞれ、
配列番号1のヌクレオチド1〜19及び配列番号2のヌクレオチド1〜19
からなる相補配列を含む、
上記RNA分子。 - 各々の鎖が23以下の塩基長を有し、標的遺伝子の転写産物であるmRNAの分解を仲介するか翻訳を阻害するのに有効な配列を有する二重鎖のRNA分子であって、前記標的遺伝子が、クラステリンをコードする遺伝子であり、前記二重鎖RNA分子の鎖がそれぞれ、
配列番号1及び配列番号2、
からなる配列を含む、
上記RNA分子。 - 前記二重鎖RNA分子の鎖がそれぞれ、
配列番号1及び配列番号2、
からなる配列からなる請求項2に記載のRNA分子。 - 請求項1から3までのいずれか一項に記載のRNA分子及び薬学的に許容される担体を含む医薬品組成物。
- 前記の薬学的に許容される担体が無菌注射液である請求項4に記載の医薬品組成物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40519302P | 2002-08-21 | 2002-08-21 | |
US60/405,193 | 2002-08-21 | ||
US40815202P | 2002-09-03 | 2002-09-03 | |
US60/408,152 | 2002-09-03 | ||
US47238703P | 2003-05-20 | 2003-05-20 | |
US60/472,387 | 2003-05-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Division JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013067754A Division JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011036267A JP2011036267A (ja) | 2011-02-24 |
JP5662766B2 true JP5662766B2 (ja) | 2015-02-04 |
Family
ID=31950539
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Expired - Fee Related JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010250838A Expired - Fee Related JP5662766B2 (ja) | 2002-08-21 | 2010-11-09 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Expired - Fee Related JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするRNAiプローブ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Country Status (10)
Country | Link |
---|---|
US (5) | US8252918B2 (ja) |
EP (2) | EP2263679B1 (ja) |
JP (4) | JP4717633B2 (ja) |
KR (3) | KR101117673B1 (ja) |
AU (1) | AU2003258426B2 (ja) |
CA (2) | CA2882443C (ja) |
IL (3) | IL166658A (ja) |
NO (2) | NO334573B1 (ja) |
NZ (1) | NZ552872A (ja) |
WO (1) | WO2004018676A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1163254T3 (da) | 1999-02-26 | 2008-06-09 | Univ British Columbia | TRPM-2 antisense-behandling |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
CA2469685C (en) | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
US7285541B2 (en) | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
JP4717633B2 (ja) * | 2002-08-21 | 2011-07-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 癌関連タンパク質を標的とするRNAiプローブ |
WO2004100977A1 (en) | 2003-03-25 | 2004-11-25 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
JP2005013221A (ja) * | 2003-06-03 | 2005-01-20 | Keio Gijuku | Braf発現抑制を利用した癌の治療 |
US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
CN101389345A (zh) * | 2004-03-19 | 2009-03-18 | 宾州研究基金会 | 治疗黑素瘤的组合方法和组合物 |
WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
EP1758999B1 (en) * | 2004-06-22 | 2011-03-09 | The Board Of Trustees Of The University Of Illinois | METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA |
KR20130137054A (ko) * | 2004-07-23 | 2013-12-13 | 퍼시픽 에지 바이오테크놀로지 엘티디. | 방광암 검출용 소변 표지 |
WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
AU2005309274B2 (en) * | 2004-11-23 | 2011-07-21 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels |
JP5376948B2 (ja) | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | 腫瘍細胞活性を調節する方法及び組成物 |
US8029980B2 (en) | 2006-09-29 | 2011-10-04 | The Board Of Trustees Of The University Of Illinois | Identification and use of agents that modulate oncogenic transcription agent activity |
WO2008088836A2 (en) * | 2007-01-16 | 2008-07-24 | The Burnham Institute For Medical Research | Compositions and methods for treatment of colorectal cancer |
US8071752B2 (en) | 2007-01-29 | 2011-12-06 | City Of Hope | Multi-targeting short interfering RNAs |
US20100112687A1 (en) * | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
US8217161B2 (en) * | 2008-04-22 | 2012-07-10 | Clemson University Research Foundation | Methods of inhibiting multiple cytochrome P450 genes with siRNA |
US8802826B2 (en) | 2009-11-24 | 2014-08-12 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
US8980261B2 (en) | 2011-02-11 | 2015-03-17 | The Rockefeller University | Treatment of angiogenesis disorders |
JP2015512877A (ja) | 2012-02-22 | 2015-04-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌を治療するためのクラステリン阻害剤とegfr阻害剤の併用 |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
CN106282185B (zh) * | 2016-08-18 | 2020-06-26 | 广州市锐博生物科技有限公司 | 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5736580A (en) * | 1980-08-13 | 1982-02-27 | Hitachi Ltd | Protecting method for converter |
CA2108144A1 (en) | 1991-03-06 | 1992-09-07 | Jack A. Roth | Methods and compositions for the selective inhibition of gene expression |
AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
US20020086386A1 (en) * | 1997-03-04 | 2002-07-04 | Kamb Carl Alexander | B-catenin assays, and compositions therefrom |
US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
DK1163254T3 (da) * | 1999-02-26 | 2008-06-09 | Univ British Columbia | TRPM-2 antisense-behandling |
WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
DE60038680T2 (de) | 1999-07-19 | 2009-05-07 | The University Of British Columbia, Vancouver | Antisense-therapie für hormonregulierte tumoren |
US6140126A (en) * | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
EP1272630A2 (en) * | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
IL151928A0 (en) * | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
IL154529A0 (en) | 2000-09-14 | 2003-09-17 | Univ British Columbia | Antisense insulin-like growth factor binding protein (igfep)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
ES2215494T5 (es) * | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
CA2433680A1 (en) * | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
CA2469685C (en) * | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
US7285541B2 (en) * | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
JP4717633B2 (ja) * | 2002-08-21 | 2011-07-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 癌関連タンパク質を標的とするRNAiプローブ |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
-
2003
- 2003-08-21 JP JP2005501198A patent/JP4717633B2/ja not_active Expired - Fee Related
- 2003-08-21 EP EP10010458.7A patent/EP2263679B1/en not_active Expired - Lifetime
- 2003-08-21 CA CA2882443A patent/CA2882443C/en not_active Expired - Fee Related
- 2003-08-21 CA CA2494766A patent/CA2494766C/en not_active Expired - Fee Related
- 2003-08-21 AU AU2003258426A patent/AU2003258426B2/en not_active Ceased
- 2003-08-21 WO PCT/CA2003/001277 patent/WO2004018676A2/en active Application Filing
- 2003-08-21 EP EP03792075A patent/EP1532249A2/en not_active Ceased
- 2003-08-21 KR KR1020107028249A patent/KR101117673B1/ko not_active IP Right Cessation
- 2003-08-21 NZ NZ552872A patent/NZ552872A/en not_active IP Right Cessation
- 2003-08-21 KR KR1020057002963A patent/KR101212512B1/ko not_active IP Right Cessation
- 2003-08-21 US US10/646,436 patent/US8252918B2/en not_active Expired - Fee Related
- 2003-08-21 KR KR1020117025408A patent/KR101238701B1/ko not_active IP Right Cessation
-
2005
- 2005-02-02 IL IL166658A patent/IL166658A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051423A patent/NO334573B1/no not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/276,300 patent/US7964717B2/en not_active Expired - Fee Related
-
2008
- 2008-05-06 US US12/116,083 patent/US7820635B2/en not_active Expired - Fee Related
-
2009
- 2009-02-22 IL IL197159A patent/IL197159A/en not_active IP Right Cessation
-
2010
- 2010-06-04 JP JP2010128382A patent/JP5171887B2/ja not_active Expired - Fee Related
- 2010-07-28 US US12/845,521 patent/US8759308B2/en not_active Expired - Fee Related
- 2010-11-09 JP JP2010250838A patent/JP5662766B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-24 US US13/404,741 patent/US9487777B2/en not_active Expired - Fee Related
- 2012-09-14 NO NO20121038A patent/NO337130B1/no not_active IP Right Cessation
-
2013
- 2013-03-28 JP JP2013067754A patent/JP2013150624A/ja active Pending
-
2014
- 2014-06-24 IL IL233352A patent/IL233352A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5662766B2 (ja) | 癌関連タンパク質を標的とするRNAiプローブ | |
JP5841332B2 (ja) | 細胞増殖阻害剤 | |
CA3161513A1 (en) | Antisense oligonucleotide targeting linc00518 for treating melanoma | |
Xing et al. | Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids | |
AU2007216630B2 (en) | RNAi probes targeting cancer-related proteins | |
JP2010529852A (ja) | 癌治療のためのNuMAのRNAi媒介ノックダウン | |
NZ538287A (en) | RNAi probes targeting cancer-related proteins | |
CA2680058C (en) | Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity | |
US9464291B2 (en) | Methods and compositions for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121030 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141006 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141020 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5662766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |